Ethos Technologies Inc. Class A Common Stock (LIFE) has upcoming FDA regulatory milestones for Efzofitimod. The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by Ethos Technologies Inc. Class A Common Stock (LIFE).
Over the past two years, Ethos Technologies Inc. Class A Common Stock has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
ATYR2810, ATYR0101, and Efzofitimod. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
ATYR2810 FDA Regulatory Events
ATYR2810 is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: Non-small cell lung cancer tumor.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ATYR2810
- Announced Date:
- November 19, 2026
- Indication:
- Non-small cell lung cancer tumor
Announcement
aTyr Pharma, Inc. announced a poster presentation featuring preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, which is being held November 18 – 21, 2026, in Seoul, South Korea.
AI Summary
aTyr Pharma announced a poster presentation of preclinical research on ATYR2810 at the Connective Tissue Oncology Society’s 2026 Annual Meeting, held November 18–21 in Seoul, South Korea. ATYR2810 is an antibody designed to block neuropilin-2 (NRP2), a receptor linked to cancer growth and spread. The research tested the drug in relevant osteosarcoma models, including models based on human patient tumors.
In mice, ATYR2810 was associated with substantially reduced tumor growth and fewer lung metastases, a serious complication of osteosarcoma. Anti-tumor effects continued after treatment stopped, with effects reported through day 45 after the drug was withdrawn on day 25. Researchers also reported no overt toxicity. NRP2 was found on cancer cells and macrophages, suggesting it may help drive disease progression. The findings support further study of NRP2 as a treatment target, but they are preclinical and do not establish that ATYR2810 is safe or effective in people.
Read Announcement
ATYR0101 FDA Regulatory Events
ATYR0101 is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: For the treatment of interstitial lung disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ATYR0101
- Announced Date:
- October 13, 2026
- Indication:
- For the treatment of interstitial lung disease
Announcement
aTyr Pharma, Inc. announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry.
AI Summary
aTyr Pharma reported that a study published in the Journal of Biological Chemistry found anti-fibrotic effects from ATYR0101, an experimental fusion protein. The research describes how the drug binds to LTBP-1, a protein in the tissue’s supporting structure, and selectively triggers the death of myofibroblasts—cells that drive scarring. This effect depended on active TGF-β, a key factor in fibrosis.
In a mouse model of lung fibrosis, ATYR0101 reduced collagen and the severity of lung scarring compared with a control treatment using nintedanib. The findings suggest the drug may do more than slow fibrosis and could help change the damaged tissue environment, though its benefits in people have not yet been established. The company says ATYR0101 has also shown anti-fibrotic effects in kidney fibrosis models. It is undergoing studies needed before clinical testing, and aTyr expects to advance it into the clinic in 2027.
Read Announcement
Efzofitimod FDA Regulatory Timeline and Events
Efzofitimod is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Efzofitimod
- Announced Date:
- September 24, 2026
- Target Action Date:
- Q4 2026
- Estimated Target Date Range:
- October 1, 2026 - December 31, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. announced that the Company expects to initiate study-related activities in the fourth quarter of 2026.
AI Summary
aTyr Pharma has reached agreement with the U.S. Food and Drug Administration on the protocol for a global Phase 3 study of efzofitimod in people with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The company expects to begin study-related activities in the fourth quarter of 2026 while preparing regulatory submissions in the United States and Europe.
The 54-week trial is planned to enroll about 372 people with moderate to severe disease. Participants will receive either efzofitimod or placebo by intravenous infusion every three weeks, while continuing stable background treatment. The primary measure will be change in lung function, assessed by forced vital capacity (FVC), at week 48. A key secondary measure will be change in the lung-related score from the King’s Sarcoidosis Questionnaire.
The design is supported by a subgroup analysis in which patients with restrictive lung disease treated with efzofitimod showed meaningful FVC benefits and improved patient-reported outcomes. aTyr says further development will require additional funding.
Read Announcement- Drug:
- Efzofitimod
- Announced Date:
- September 24, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
AI Summary
aTyr Pharma has reached agreement with the U.S. Food and Drug Administration on the protocol for a global Phase 3 study of efzofitimod in people with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The company expects to begin study-related activities in the fourth quarter of 2026 while preparing regulatory submissions in the United States and Europe.
The 54-week trial is planned to enroll about 372 people with moderate to severe disease. Participants will receive either efzofitimod or placebo by intravenous infusion every three weeks, while continuing stable background treatment. The primary measure will be change in lung function, assessed by forced vital capacity (FVC), at week 48. A key secondary measure will be change in the lung-related score from the King’s Sarcoidosis Questionnaire.
The design is supported by a subgroup analysis in which patients with restrictive lung disease treated with efzofitimod showed meaningful FVC benefits and improved patient-reported outcomes. aTyr says further development will require additional funding.
Read Announcement- Drug:
- Efzofitimod
- Announced Date:
- September 1, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. today provided an update on the expected timing of a response from the U.S. Food and Drug Administration (FDA) related to the protocol the Company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
AI Summary
aTyr Pharma expects to receive an FDA response by mid-September 2026 about the protocol it submitted in June for a planned Phase 3 trial of efzofitimod. The study would test the treatment in people with moderate to severe pulmonary sarcoidosis, a lung disease that can cause inflammation and scarring. The company’s timing estimate is based on FDA feedback.
The proposed global trial would last 54 weeks and enroll up to about 372 people with symptomatic disease and restrictive lung impairment. Participants would be randomly assigned to receive either efzofitimod at 5.0 mg per kilogram or a placebo, by intravenous infusion every three weeks for 17 doses. Patients would continue their stable background treatment, such as a low-dose oral steroid or another immune-suppressing medicine. The main measure would be change in lung capacity at week 48. A key secondary measure would assess changes in lung-related quality of life. The trial design and timing remain subject to further development.
Read Announcement- Drug:
- Efzofitimod
- Announced Date:
- July 15, 2026
- Indication:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Announcement
aTyr Pharma, Inc. announced that the Company will present a subgroup analysis of the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease, at the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) 2026 Congress, which is scheduled to take place July 15 – 17, 2026, in Porto, Portugal.
AI Summary
aTyr Pharma said it will present a subgroup analysis from its Phase 3 EFZO-FIT™ study of efzofitimod at the 2026 WASOG Congress in Porto, Portugal, from July 15 to 17, 2026. The analysis focuses on patients with pulmonary sarcoidosis, a serious form of interstitial lung disease that can make breathing harder over time.
According to the company, patients with restrictive lung disease showed clinically meaningful improvement in forced vital capacity, or FVC, along with better results on multiple patient-reported outcome measures when treated with 5.0 mg/kg efzofitimod compared with placebo. These findings suggest the drug may help improve lung function and symptoms in this hard-to-treat group.
aTyr also said it submitted a protocol to the FDA in June 2026 for a planned Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The poster details will be available on the company’s website after the presentation.
Read Announcement